Related Experiment Video
Updated: Jul 17, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Clinical Audit of Denosumab Biosimilar for Aggressive GCT of Bone: A Tertiary Care Center Retrospective Analysis
Rajesh B Singh1, Saravana K Jagannathan1, Kumar Vineet2
1Surgical Oncology (Orthopedics Oncology), Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India.
Objectives:
Giant cell tumor of bone (GCTB) is a locally aggressive tumor with a high recurrence rate. Using denosumab or its biosimilar in a neoadjuvant setting can facilitate limb-preserving surgery and reduce recurrence rates, with minimal side effects.
Material And Methods:
In this clinical audit, we retrospectively analyzed the impact of denosumab biosimilar (DB) on Campanacci grade 3 GCTB, the most aggressive form of these tumors.
Statistical Analysis:
Means and standard deviations were used for normally distributed continuous variables, medians and ranges for nonnormal continuous variables, and percentages for categorical variables.
Results:
All cases received two doses of DB on days 0 and 14, resulting in a mean lesion size reduction of 17.75%.
Conclusion:
Our findings suggest that this treatment regimen can significantly improve outcomes for patients with aggressive GCTB, aiding orthopaedic oncologists in managing these challenging cases more effectively.
